Before the Open (Dec 11)

Good morning. Happy Monday. Hope you had a good weekend.
The Asian/Pacific markets closed mostly up. China, Hong Kong and Singapore gained more than 1%; Japan, India, New Zealand, Taiwan and the Philippines also did well. Europe, Africa and the Middle East are current mixed. Turkey and Russia are up more than 1%; the UK, the UAE, Israel, Austria and Sweden are also doing well. Poland, Greece, Hungary, Saudi Arabia and Romania are down. Futures in the States point towards a flat open for the cash market.
—————
VIDEO: LeavittBrothers.net Overview
—————
The dollar is down. Oil is up; copper is flat. Gold and silver are mixed and little changed. Bonds are up.
Stock headlines from barchart.com…
Automatic Data Processing (ADP +0.12%) was upgraded to ‘Buy’ from ‘Neutral’ at Goldman Sachs with a price target of $135.
DaVita (DVA +0.85%) was upgraded to ‘Buy’ from ‘Neutral’ at Citigroup.
First Solar (FSLR +2.32%) was upgraded to ‘Outperform’ from ‘Neutral’ at Baird with a price target of $82.
Kimberly-Clark (KMB +0.29%) was downgraded to ‘Sell’ from ‘Neutral’ at Citigroup.
Hologic (HOLX +2.42%) was upgraded to ‘Outperform’ from ‘Market Perform’ at Cowen with a price target of $51.
Flowserve (FLS -1.22%) was downgraded to ‘Hold’ from ‘Buy’ at Stifel.
Waste Management ({=WM =}) was upgraded to ‘Buy’ from ‘Hold’ at Stifel with a price target of $95.
Overstock.com (OSTK -1.25%) climbed nearly 4% in after-hours trading after Morgan Stanley reported an 11.4% passive stake in the company.
Cytokinetics (CYTK -1.23%) dropped 5% in after-hours trading after it said that the results of a Phase 3 trial of its Tirasemtiv in patients with amyorophic lateral sclerosis did not meet primary or secondary endpoints.
UTStarcom Holdings (UTSI +0.77%) rallied almost 8% in after-hours trading after Tonghao Group reported a 9.9% stake in the company.
Fate Therapeutics (FATE -0.48%) rose over 6% in after-hours trading after it announced the dosing of its first subject in the “Apollo” study of FATE-NK100 as a monotherapy for the treatment of refractory or relapsed acute myelogenous leukemia.
Akari Therapeutics PLC (AKTX -2.78%) jumped 14% in after-hours trading after is said a Phase II trial of its Coversin in patients with paroxysmal nocturnal hemoglobinuria met its primary endpoint.
Today’s Economic Calendar
10:00 Job Openings and Labor Turnover Survey
1:00 PM Results of $20B, 10-Year Note Auction
Other…
today’s upgrades/downgrades from briefing.com
this week’s Earnings from Morningstar
this week’s Economic Numbers/Reports powered by ECONODAY